surmount-1 tirzepatide 15 mg weight loss percent 72 weeks (NEJM 2022) tested — a dual GIP/GLP-1 Tirzepatide Was Associated with Improved

"Physicians are ultimately the gatekeepers of this, and hopefully there will be responsible prescribing for the medication," Ur said

It retards digestion

The CONQUER trial (Gadde et al., 2011) enrolled over 2,400 adults with obesity and at least two weight-related comorbidities, demonstrating that participants receiving the higher-dose combination (phentermine 15 mg/topiramate 92 mg) achieved mean weight loss of approximately 910% of baseline body weight at 56 weeks, compared to 12% with placebo

Regulation of growth hormone secretion

There is one disclaimer that bears mentioning: the primary side effect of Semaglutide is nausea